Market Overview

UPDATE: D.A. Davidson Upgrades Dycom Industries Following Q4 FY13 EPS Report

Share:

In a report published Thursday, D.A. Davidson analyst John B. Rogers upgraded the rating on Dycom Industries (NYSE: DY) from Neutral to Buy, and raised the price target from $26.00 to $30.00.

In the report, D.A. Davidson noted, “Dycom reported EPS of $0.43 for the company's Q4 FY13, modestly below our estimate of $0.46 per share although up from $0.39 last year. The company reported a sharp increase in revenue, up 50%, due to a recent acquisition, but also improved organic growth of 7%...We are revising our earnings expectations, as indicated below and shown in the attached model. Our near-term quarterly estimates have been reduced to incorporate slightly lower margin assumptions due to integration and other costs as well as a higher share count, partially offset by higher revenue growth expectations.”

Dycom Industries closed on Thursday at $24.77.

Latest Ratings for DY

DateFirmActionFromTo
Sep 2019MaintainsOutperform
Aug 2019MaintainsBuy
Jun 2019MaintainsBuy

View More Analyst Ratings for DY
View the Latest Analyst Ratings

Posted-In: D.A. Davidson John B. RogersAnalyst Color Upgrades Analyst Ratings

 

Related Articles (DY)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
IINDoughertyAssumes34.0
PNRJefferiesInitiates Coverage On
YYUBSUpgrades
ROKUOppenheimerMaintains155.0
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

FDA Approves Third Drug in BD Simplist Prefilled Injectable Line of Products

UPDATE: Topeka Raises PT on Heico Following Stronger F3Q13 Report